A Phase 2 interventional study of XmAb5871 in IgG4-RD, sponsored by Xencor, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by Xencor, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 4 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.
Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 2, and was the 3rd registered.
72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →4 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Brazil, China and 5 more countries
Ages 2–18
Acepodia Biotech, Inc. · Sites in United States, China, Japan
Ages 18+
Sanofi · Sites in United States, Argentina, Belgium and 16 more countries
Ages 18+
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Immunoglobulin G4-Related Disease studies recruiting now, 12 (43%) set no upper age limit and 13 (46%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 18 across the 12 interventional studies, 1,506 across the 2 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 10 most frequent:
Xencor, Inc. is the lead sponsor of 30 studies on the registry; 7 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 2 (13%) have results posted.
Xencor, Inc. has 1 study filed under Immunoglobulin G4-Related Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
XmAb5871 administered by IV infusion for up to a total of 12 infusions
Biological: XmAb5871
Proportion of Patients With an Improvement in IgG4-RD Activity
Improvement of disease activity as defined by a decrease of IgG4-RD responder index \>= 2 points from Day 1 pre-dose disease activity score. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.
Time frame: Baseline Day 1 to Day 169
Number of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3
The number of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3 will be tabulated according to MedDRA system-organ class and preferred term, intensity and causality.
Time frame: Baseline Day 1 to Day 197
| Milestone | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose |
|---|---|---|
| Started | 15 | 5 |
| Completed | 12 | 4 |
| Not completed | 3 | 1 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 |
Improvement of disease activity as defined by a decrease of IgG4-RD responder index \>= 2 points from Day 1 pre-dose disease activity score. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.
| Participants | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose |
|---|---|---|
| Responder at Day 169 visit | 12 | 4 |
| Non-Responder at Day 169 visit | 2 | 0 |
| Not Assessed at Day 169 visit | 1 | 1 |
The number of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3 will be tabulated according to MedDRA system-organ class and preferred term, intensity and causality.
| Participants | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose |
|---|---|---|
| Number of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3 | 13 | 5 |
Collected over Day 1 (First Dose) through Day 197. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XmAb5871 5 mg/kg | 0/15 (0%) | 1/15 (6.7%) | 7/15 (46.7%) |
| XmAb5871 Fixed Dose | 0/5 (0%) | 1/5 (20%) | 3/5 (60%) |
| Event | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose |
|---|---|---|
| Chronic inflammatory demyelinating polyradiculoneuropathyNervous system disorders | 0/15 | 1/5 |
| Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/5 |
| PneumoniaInfections and infestations | 1/15 | 0/5 |
| Event | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose |
|---|---|---|
| NauseaGastrointestinal disorders | 2/15 | 2/5 |
| VomitingGastrointestinal disorders | 1/15 | 2/5 |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 2/5 |
| Abdominal painGastrointestinal disorders | 3/15 | 1/5 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/15 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 2/15 | 0/5 |
| ChillsGeneral disorders | 2/15 | 0/5 |
| HeadacheNervous system disorders | 2/15 | 0/5 |
| Age, Continuous(years) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Mean | 60.1 ± 10.57 | 51.2 ± 14.11 | 57.9 ± 11.82 |
| Sex: Female, Male(Participants) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 10 | 4 | 14 |
| Ethnicity (NIH/OMB)(Participants) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 15 | 5 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 12 | 3 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| United States | 15 | 5 | 20 |
| Serum IgG4 level at Baseline(mg/dL) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Mean | 440.33 ± 622.990 | 858.60 ± 351.608 | 544.90 ± 588.674 |
| Involved Areas at Baseline(Participants) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Bile Ducts | 2 | 0 | 2 |
| Constitutional Symptoms | 6 | 1 | 7 |
| Heart / Pericardium | 3 | 0 | 3 |
| Kidney | 5 | 1 | 6 |
| Lacrimal Glands | 7 | 3 | 10 |
| Lungs | 4 | 2 | 6 |
| Lymph Nodes | 10 | 4 | 14 |
| Nasal Cavity Lesion | 3 | 0 | 3 |
| Orbital Lesion | 2 | 1 | 3 |
| Other | 4 | 4 | 8 |
| Other ENT Lesions, e.g. tonsillitis, pharyngitis | 2 | 0 | 2 |
| Other Salivary Glands | 1 | 0 | 1 |
| Pancreas | 1 | 3 | 4 |
| Parotid Glands | 8 | 2 | 10 |
| Retroperitoneal Fibrosis | 1 | 1 | 2 |
| Sinusitis | 2 | 2 | 4 |
| Skin | 0 | 1 | 1 |
| Submandibular Glands | 9 | 3 | 12 |
| Baseline IgG4-RD Responder Index Total Activity Score(Total Activity Score) | XmAb5871 5 mg/kg | XmAb5871 Fixed Dose | Total |
|---|---|---|---|
| Mean | 11.5 ± 6.65 | 12.8 ± 6.42 | 11.8 ± 6.45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2016 to primary completion in Dec 2017, 21 months.
Results were first posted in Dec 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obexelimab
Immunoglobulin G4-Related Disease →